Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Effectiveness and infectious complications of BCMA T-cell engagers in treating multiple myeloma : Real-world evidence from Sweden

Uttervall, Katarina ; Tätting, Love ; Lemonakis, Konstantinos LU ; Majd, Mousa ; Crafoord, Jacob ; Olsson, Mikael ; Mellqvist, Ulf Henrik ; Hansson, Markus LU orcid and Nahi, Hareth (2024) In Cancer Medicine 13(8).
Abstract

Background: Multiple myeloma (MM), an incurable disease characterized by frequent relapses and a need for multiple treatments, often progresses to a relapse/refractory status resistant to all available drugs and drug classes. Bispecific antibodies, specifically BCMA T-cell engagers, have emerged as effective treatments for MM, demonstrating impressive efficacy. However, these treatments can adversely affect the immune system, increasing vulnerability to infections. Methods/Results: This study evaluated the efficacy and safety of BCMA T-cell engagers in 58 Swedish patients with poor MM prognosis. The patients exhibited a 69% overall response rate, with 69% survival and 60% progression-free survival at 15 months. Conclusions: Despite the... (More)

Background: Multiple myeloma (MM), an incurable disease characterized by frequent relapses and a need for multiple treatments, often progresses to a relapse/refractory status resistant to all available drugs and drug classes. Bispecific antibodies, specifically BCMA T-cell engagers, have emerged as effective treatments for MM, demonstrating impressive efficacy. However, these treatments can adversely affect the immune system, increasing vulnerability to infections. Methods/Results: This study evaluated the efficacy and safety of BCMA T-cell engagers in 58 Swedish patients with poor MM prognosis. The patients exhibited a 69% overall response rate, with 69% survival and 60% progression-free survival at 15 months. Conclusions: Despite the risk of infectious complications, the prognosis of MM patients can be significantly improved with vigilant monitoring and proactive management of infections. This real-world data highlight the potential of BCMA T-cell engagers in treating MM, emphasizing the need for careful patient monitoring to mitigate infection risks.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
bispecific antibodies, immunotherapy, multiple myeloma, real-world data
in
Cancer Medicine
volume
13
issue
8
article number
e7048
publisher
Wiley-Blackwell
external identifiers
  • scopus:85191077419
  • pmid:38651177
ISSN
2045-7634
DOI
10.1002/cam4.7048
language
English
LU publication?
yes
id
1e5361d1-2eb0-493e-b321-ce9c2ab5dfbf
date added to LUP
2024-05-03 14:15:49
date last changed
2025-01-11 16:32:11
@article{1e5361d1-2eb0-493e-b321-ce9c2ab5dfbf,
  abstract     = {{<p>Background: Multiple myeloma (MM), an incurable disease characterized by frequent relapses and a need for multiple treatments, often progresses to a relapse/refractory status resistant to all available drugs and drug classes. Bispecific antibodies, specifically BCMA T-cell engagers, have emerged as effective treatments for MM, demonstrating impressive efficacy. However, these treatments can adversely affect the immune system, increasing vulnerability to infections. Methods/Results: This study evaluated the efficacy and safety of BCMA T-cell engagers in 58 Swedish patients with poor MM prognosis. The patients exhibited a 69% overall response rate, with 69% survival and 60% progression-free survival at 15 months. Conclusions: Despite the risk of infectious complications, the prognosis of MM patients can be significantly improved with vigilant monitoring and proactive management of infections. This real-world data highlight the potential of BCMA T-cell engagers in treating MM, emphasizing the need for careful patient monitoring to mitigate infection risks.</p>}},
  author       = {{Uttervall, Katarina and Tätting, Love and Lemonakis, Konstantinos and Majd, Mousa and Crafoord, Jacob and Olsson, Mikael and Mellqvist, Ulf Henrik and Hansson, Markus and Nahi, Hareth}},
  issn         = {{2045-7634}},
  keywords     = {{bispecific antibodies; immunotherapy; multiple myeloma; real-world data}},
  language     = {{eng}},
  number       = {{8}},
  publisher    = {{Wiley-Blackwell}},
  series       = {{Cancer Medicine}},
  title        = {{Effectiveness and infectious complications of BCMA T-cell engagers in treating multiple myeloma : Real-world evidence from Sweden}},
  url          = {{http://dx.doi.org/10.1002/cam4.7048}},
  doi          = {{10.1002/cam4.7048}},
  volume       = {{13}},
  year         = {{2024}},
}